AbbVie to Acquire Aliada Therapeutics for $1.4 Billion, Expanding Alzheimer's Pipeline
The acquisition will allow AbbVie to accelerate development of ALIA-1758, a potential disease-modifying therapy for Alzheimer ...
Daily3d
AbbVie to acquire Aliada Therapeutics for USD 1.4 billion in cash
AbbVie and Aliada Therapeutics have announced a definitive agreement under which AbbVie will acquire Aliada, a biotechnology ...
biopharma-reporter5d
AbbVie acquires Aliada Therapeutics in $1.4 billion deal
The acquisition of Aliada Therapeutics will grant AbbVie access to a neuroscience-focused technology platform and an ...
PharmiWeb6d
AbbVie to Acquire Aliada Therapeutics, Strengthening Focus in Alzheimer's Disease and Neuroscience Pipeline
AbbVie (NYSE: ABBV) and Aliada Therapeutics today announced a definitive agreement under which AbbVie will acquire Aliada, a ...
PMLiVE5d
AbbVie to expand neuroscience pipeline with $1.4bn Aliada Therapeutics acquisition
AbbVie has announced that it will be acquiring Aliada Therapeutics for $1.4bn, marking a notable boost to its neuroscience ...
The Pharma Letter6d
AbbVie punts $1.4 billion to buy early-stage Alzheimer’s drug developer Aliada
US Pharma major AbbVie has reached a definitive agreement to acquire Aliada Therapeutics, a biotech advancing therapies using ...
labiotech19h
Top biotech deals of October 2024
Discover the major biotech partnerships, collaborations, and mergers and acquisitions that made headlines in October 2024.
Cautious Hold Rating on AbbVie Amid Uncertainty of Aliada Acquisition’s Long-term Impact
Leerink Partners analyst David Risinger has maintained their neutral stance on ABBV stock, giving a Hold rating on October 18. David Risinger ...
Deal Watch: Davis Polk, Wachtell Work Multiple Big Deals as Election Economics Become Focus for Dealmakers
In past presidential elections, in the year after Election Day, M&A and debt capital markets activity have diverged in their ...